Literature DB >> 1398227

Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

J Jankowski1, G Coghill, D Hopwood, K G Wormsley.   

Abstract

While the activation of the proto-oncogenes has been implicated in the development and progression of cancer of many tissues, the role of oncogenes in the development of oesophageal adenocarcinoma has not been defined. Fifteen patients who had undergone resection for oesophageal adenocarcinoma and 15 who had undergone oesophagectomy or biopsy for Barrett's oesophagus were studied. The latter patients also had adjacent normal gastric mucosa biopsied for comparison with the metaplastic oesophageal mucosa. The mucosal samples were snap frozen and subsequently stained with monoclonal antibodies to the following oncogene associated proteins; c-erbB2 (neu and CE-1) (external domain), c-erbB2 (NCL-CB11) (internal domain), c-src, c-ras, c-myc, c-fos, c-jun, and the onco-suppressor gene--p53. All tumours were well or moderately differentiated adenocarcinomas arising from the lower third of the oesophagus. Eleven specimens showed strong membraneous staining with both c-erbB2 (neu) and c-erbB2 (CBL-CB11). Seven specimens showed strong nuclear staining with p53 onco-suppressor gene. Three specimens were positive for c-ras and c-src, and two were positive for c-jun. In Barrett's epithelium, nine specimens were positive for c-erbB2 (neu and CB11), three were positive for c-src, two were positive for c-ras and c-jun, and one was positive for c-fos. Two of the gastric mucosal biopsy specimens expressed c-erbB2 weakly but no other oncogenes were found. The frequency of positive staining for c-erbB2 is very high, compared with the expression of these genes in other tumours. It is also concluded that errors in the onco-suppressor gene p53, and especially in the external and internal domains of c-erbB2, which is also often expressed in Barrett's mucosa, may be implicated in the development of adenocarcinoma of the oesophagus.

Entities:  

Mesh:

Year:  1992        PMID: 1398227      PMCID: PMC1379437          DOI: 10.1136/gut.33.8.1033

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor.

Authors:  N J Maihle; T W Flickinger; M A Raines; M L Sanders; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.

Authors:  W E Mercer; M T Shields; D Lin; E Appella; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

Review 3.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.

Authors:  W J Gullick
Journal:  Br Med Bull       Date:  1991-01       Impact factor: 4.291

4.  Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma.

Authors:  Y Yonemura; I Ninomiya; S Ohoyama; H Kimura; A Yamaguchi; S Fushida; T Kosaka; K Miwa; I Miyazaki; Y Endou
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

5.  Optimal preservation of p21 ras immunoreactivity and morphology in paraffin-embedded tissue.

Authors:  J J Going; A R Williams; A H Wyllie; T J Anderson; J Piris
Journal:  J Pathol       Date:  1988-07       Impact factor: 7.996

6.  Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene.

Authors:  K Yanagihara; T Seyama; M Tsumuraya; N Kamada; K Yokoro
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Induction of protooncogene c-jun by serum growth factors.

Authors:  K Ryder; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

9.  Expression of the ras oncoprotein in gastric carcinomas and adjacent mucosa.

Authors:  M Karayiannis; M Yiagnisis; K Papadimitriou; D A Spandidos
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

Review 10.  Growth regulation of the PCNA gene.

Authors:  R Baserga
Journal:  J Cell Sci       Date:  1991-04       Impact factor: 5.285

View more
  26 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Structural and functional aspects of the multiplicity of Neu differentiation factors.

Authors:  D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

Review 4.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

5.  Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus.

Authors:  J Jankowski
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

6.  p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

Authors:  A G Casson; M Tammemagi; S Eskandarian; M Redston; J McLaughlin; H Ozcelik
Journal:  Mol Pathol       Date:  1998-04

7.  Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Authors:  Agnieszka M Rygiel; Francesca Milano; Fiebo J Ten Kate; Jacques J G H M Bergman; Kausillia K Krishnadath
Journal:  J Oncol       Date:  2010-06-09       Impact factor: 4.375

Review 8.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

9.  Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus.

Authors:  J R Stewart; S J Hoff; D H Johnson; M J Murray; D R Butler; C C Elkins; K W Sharp; W H Merrill; J L Sawyers
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

Review 10.  Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

Authors:  H J Stein; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.